What is Zacks Research's Estimate for ALNY FY2027 Earnings?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) - Analysts at Zacks Research issued their FY2027 earnings estimates for shares of Alnylam Pharmaceuticals in a research note issued to investors on Thursday, March 6th. Zacks Research analyst A. Chakraborty forecasts that the biopharmaceutical company will post earnings of $2.39 per share for the year. The consensus estimate for Alnylam Pharmaceuticals' current full-year earnings is ($1.70) per share.

Other equities research analysts have also issued reports about the company. Needham & Company LLC reaffirmed a "buy" rating and set a $320.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 26th. HC Wainwright raised their price target on Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the company a "buy" rating in a research note on Monday, February 24th. JPMorgan Chase & Co. upped their price objective on shares of Alnylam Pharmaceuticals from $272.00 to $280.00 and gave the stock a "neutral" rating in a research note on Tuesday. Wolfe Research downgraded shares of Alnylam Pharmaceuticals from a "peer perform" rating to an "underperform" rating in a research report on Tuesday, November 12th. Finally, William Blair reaffirmed an "outperform" rating on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 26th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $304.26.

Remove Ads

Alnylam Pharmaceuticals Trading Up 2.4 %

Shares of Alnylam Pharmaceuticals stock traded up $5.67 on Friday, hitting $238.74. 603,109 shares of the company traded hands, compared to its average volume of 790,668. Alnylam Pharmaceuticals has a 52 week low of $141.98 and a 52 week high of $304.39. The company has a market cap of $30.91 billion, a PE ratio of -110.02 and a beta of 0.39. The stock's 50 day moving average price is $254.64 and its 200-day moving average price is $260.93. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03).

Institutional Trading of Alnylam Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in ALNY. Huntington National Bank increased its stake in Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 45 shares during the last quarter. Hollencrest Capital Management purchased a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth $29,000. Larson Financial Group LLC grew its holdings in shares of Alnylam Pharmaceuticals by 187.2% during the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 73 shares during the period. Park Square Financial Group LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $28,000. Finally, R Squared Ltd purchased a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at about $33,000. Institutional investors and hedge funds own 92.97% of the company's stock.

Insider Activity at Alnylam Pharmaceuticals

In related news, CMO Pushkal Garg sold 1,752 shares of the firm's stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $251.00, for a total transaction of $439,752.00. Following the completion of the sale, the chief marketing officer now directly owns 15,705 shares in the company, valued at approximately $3,941,955. This trade represents a 10.04 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.21, for a total transaction of $169,204.23. Following the transaction, the executive vice president now directly owns 14,321 shares in the company, valued at $3,654,862.41. This trade represents a 4.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 72,986 shares of company stock valued at $20,397,849. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.